Time for some more speculation with the tinfoil hat mode on, so maybe take this with a grain of 
, but Novartis has dropped some pretty interesting candidates from its pipeline. https://www.fiercebiotech.com/biotech/novartis-shakes-early-pipeline-6-assets-nixed-and-2-new-cancer-candidates
Four of the dropped assets are in solid tumor indications, and include AAA802 in prostate cancer, MGY825 in non-small cell lung cancer and KFA115 and HRO761 in unspecified solid tumors, according to a Novartis presentation (PDF) from the third quarter of 2025.
The other two culled candidates are DFV890, an NLRP3 inhibitor in development for low-risk myelodysplastic syndrome, and PIT565 for B-cell malignancies.
These pipeline culls are “balanced by the addition of new projects entering our pipeline,” the spokesperson added. “We continue to advance approximately 99 projects in clinical development.”